母体N末端B型利钠肽原对子痫前期孕妇严重母体不良结局的预测价值
本研究为回顾性队列研究,纳入2018年1月至2023年12月在维也纳医科大学评估的130例≤36周确诊子痫前期的单胎妊娠,检测诊断时母体血清NT-proBNP、sFlt-1和PlGF水平。13例(10%)发生严重母体不良结局,其NT-proBNP中位数显著高于无不良结局组(688.0 pg/mL vs 106.1 pg/mL,P<0.001)。校正采样孕周和sFlt-1/PlGF比值Z评分后,NT-proBNP Z评分与严重母体不良结局显著相关(校正OR 3.24,95%CI 1.50-7.84;P=0.005),并预测更短的分娩时间(校正HR 3.08,95%CI 1.47-6.44;P=0.003)。结论认为NT-proBNP是子痫前期孕妇严重母体不良结局和分娩时间的强预测因子,尤其在早发型病例中,可能作为临床可及的风险分层和监测生物标志物。
要点
- 子痫前期确诊时NT-proBNP升高与严重母体不良结局风险增加独立相关(校正OR 3.24)。
- NT-proBNP对严重母体不良结局的判别能力优于sFlt-1/PlGF比值(AUC 0.75 vs 0.67)。
- NT-proBNP联合采样孕周可提高判别能力(AUC 0.82 vs 0.76)。
核心结论
- NT-proBNP是确诊子痫前期孕妇严重母体不良结局和分娩时间的强预测因子,尤其在早发型病例中。
- NT-proBNP可能作为确诊子痫前期孕妇风险分层和监测的临床可及生物标志物。
研究设计与样本
- 回顾性队列研究,纳入2018年1月至2023年12月在维也纳医科大学评估的≤36周确诊子痫前期的单胎妊娠。
- 共纳入130例孕妇,在子痫前期诊断时检测母体血清NT-proBNP、sFlt-1和PlGF水平。
- 主要结局为严重母体不良事件,包括入住重症监护室、母体死亡、肺水肿和严重神经系统并发症。
- 采用logistic和Cox回归模型分析严重母体不良结局与NT-proBNP及sFlt-1/PlGF比值Z评分的关联,校正采样孕周和另一生物标志物Z评分。
- 采用受试者工作特征曲线下面积(AUC)评估生物标志物的判别能力。
主要发现
- 130例孕妇中13例(10%)发生严重母体不良结局。
- 严重母体不良结局组NT-proBNP中位数为688.0 pg/mL(四分位距249.6-1038.0),无不良结局组为106.1 pg/mL(四分位距50.6-280.6),组间差异显著(P<0.001)。
- 校正采样孕周和sFlt-1/PlGF比值Z评分后,较高NT-proBNP Z评分与严重母体不良结局显著相关(校正OR 3.24,95%CI 1.50-7.84;P=0.005)。
- 校正后较高NT-proBNP Z评分预测更短的分娩时间并发生严重母体不良结局(校正HR 3.08,95%CI 1.47-6.44;P=0.003)。
- sFlt-1/PlGF比值与上述结局无显著关联;ROC曲线分析显示NT-proBNP判别能力优于sFlt-1/PlGF比值(AUC 0.75,95%CI 0.61-0.90 vs 0.67,95%CI 0.56-0.79);两者联合采样孕周后判别能力均提高(AUC 0.82,95%CI 0.71-0.94 vs 0.76,95%CI 0.65-0.88)。
临床怎么用
- 作者认为NT-proBNP可能作为确诊子痫前期孕妇风险分层和监测的临床可及生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre-eclampsia (PE). This study aimed to evaluate the predictive value of NT-proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE. METHODS: This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT-proBNP, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z-scores for NT-proBNP and the sFlt-1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z-score of the other biomarker. The area under the receiver-operating-characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers. RESULTS: Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT-proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6-1038.0) pg/mL vs 106.1 (IQR, 50.6-280.6) pg/mL; P < 0.001). Higher NT-proBNP Z-score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50-7.84); P = 0.005) and predicted shorter time-to-delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47-6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt-1/PlGF ratio Z-score. The sFlt-1/PlGF ratio was not associated significantly with these outcomes. ROC-curve analysis showed that NT-proBNP had superior discriminative performance compared with the sFlt-1/PlGF ratio (AUC, 0.75 (95% CI, 0.61-0.90) vs 0.67 (95% CI, 0.56-0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71-0.94) vs 0.76 (95% CI, 0.65-0.88)). CONCLUSION: NT-proBNP was a strong predictor of severe maternal adverse outcome and time-to-delivery in women diagnosed with PE, especially in early-onset cases. NT-proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Palmrich P, Kalafat E, Schirwani-Hartl N, et al. Prognostic value of maternal N-terminal pro-B-type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre-eclampsia. Ultrasound Obstet Gynecol. 2025. PMID: 41206530. doi:10.1002/uog.70129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。